---
title: "GSK eyes future growth with cost-cutting plan amid promising Q2"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294228897.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-07-29T14:01:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294228897.md)
  - [en](https://longbridge.com/en/news/294228897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294228897.md)
---

# GSK eyes future growth with cost-cutting plan amid promising Q2

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [GSK now expects 20+ phase III trial starts in 2026, up from 10](https://longbridge.com/en/news/294056670.md)
- [GSK: Strong core growth in Q2 2026, robust R&D acceleration, and major restructuring underway](https://longbridge.com/en/news/294062275.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)